Latest News

Tiziana Responds to UK Call for Development of Innovative ‘Take Home’ Treatments for COVID-19 Disease

17 June 2021

NEW YORK & LONDON, June 17, 2021 — Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases announces that it has submitted a grant to the United...

Read more

Posting of Notice of Annual General Meeting

02 June 2021

For immediate release

2 June 2021

The Company announces that a letter to Shareholders has been posted advising that the Notice of Annual General Meeting has been made available on the Company’s website: https://ir.tizianalifesciences.com/shareholder-services/annual-general-meeting

The AGM is to be held on...

Read more

Tiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers.

26 May 2021

New York/London, 26 May 2021 – Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory diseases and cancers, today provided an update on further analysis of lymphocyte subsets...

Read more

Tiziana Life Sciences Announces Initiation of Clinical Trial in a Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Progr

25 May 2021

  • The first patient with SPMS was dosed on May 24, 2021 with nasally administered Foralumab. The treatment regimen will continue for six months to examine long-term safety, tolerability and clinical responses.
  • ...

Read more

PDMR Dealing

21 May 2021

London, New York, 21 May 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified...

Read more

Final Results for the Year Ended 31 December 2020

18 May 2021

London / New York 18 May 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), (the "Company" or "Tiziana"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces its financial results for...

Read more

Page 1 of 27 Next